Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-world
Berotralstat was associated with significant and sustained reductions in attack rates among patients with HAE, regardless of baseline attack rate. Patients with 0 baseline attacks/month maintained low attack rates following berotralstat initiation.
Authors
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Sandra Nestler-Parr
- Sean D. MacKnight (ORCID: https://orcid.org/0000-0001-5032-2110)
- Raffi Tachdjian (ORCID: https://orcid.org/0000-0002-5387-0013)
- Mark Davis‐Lorton (ORCID: https://orcid.org/0000-0002-0116-562X)
- Patrick Gillard
- Meri LiVecchi
- William R. Lumry
- Ramya Ramasubramanian
- Lorena Lopez-Gonzalez
Institutions
- University of California, Los Angeles (US)
- ENT and Allergy (US)
- BioCryst Pharmaceuticals (United States) (US)
- Group for Research in Decision Analysis (CA)
- Allergy Associates Research Center (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Allergy Asthma and Clinical Immunology
- Published
- 2026-01-25
- DOI
- https://doi.org/10.1186/s13223-025-01005-x
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00